SBI Securities’s Kalaris Therapeutics KLRS Stock Holding History

SBI Securities’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20	Hold	5	–	–	﹤0.01%	3849
2026 Q1	$29	Hold	5	–	–	﹤0.01%	3687
2025 Q4	$42	Sell	5 -3	-38%	-$19	﹤0.01%	3617
2025 Q3	$46	Sell	8 -2	-20%	-$7	﹤0.01%	3746
2025 Q2	$27	Buy	+10	New	+$45	﹤0.01%	3864
2025 Q1	–	Sell	-1	Closed	-$8	–	4227
2024 Q4	$8	Buy	+1	New	+$15	﹤0.01%	3960

Other funds holding KLRS

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

FCA

Fortis Capital Advisors Prairie Village, Kansas $889M AUM 36.31% 1-Year Est. Return

WAM

WealthTrust Asset Management Destin, Florida $185M AUM 26.82% 1-Year Est. Return

SBI Securities's KLRS Position: Q2 2026 in Review

SBI Securities held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 5 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #3849.

SBI Securities first reported a position in KLRS in Q4 2024 and has held it in 6 quarters since. The position peaked at $46 in Q3 2025. 4 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

SBI Securities held 5 shares of Kalaris Therapeutics worth $20 as of Q2 2026.
SBI Securities left its Kalaris Therapeutics share count unchanged in Q2 2026.
Kalaris Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3849 holding.
SBI Securities first reported a position in Kalaris Therapeutics in Q4 2024 and has held it in 6 quarters since.
SBI Securities's Kalaris Therapeutics position peaked at $46 in Q3 2025.
4 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.